-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The third quarter of 2021 has ended.
Looking back at this quarter, the domestic new drug R&D field is still active in financing.
A total of more than 80 companies have completed different rounds and types of financing.
From the perspective of the main R&D areas, cell therapy, Gene editing is frequently favored by capital
.
Cell technology is known as the third revolution in human medical history.
Cell therapy has great potential in cancer treatment.
Among them, chimeric antigen receptor-loaded T cell (CAR-T) therapy is more effective for patients with advanced tumors.
The good curative effect has led to an upsurge in immune cell therapy
.
2021 is the first year of the commercialization of domestic CAR-T cells.
Two domestic CAR-T products have been approved for listing.
The industry expects that CAR-T cell therapy is expected to usher in a major outbreak this year
.
In this context, capital is also accelerating its deployment in the field of cellular immunotherapy
.
For example, on July 30 this year, the newly established Xingyiang Biotech announced the completion of a US$40 million angel round of financing led by Eli Lilly Asia Fund.
This round of investment was led by Eli Lilly Asia Fund, IDG Capital and Sherpa Investment Follow the vote
.
Xingyiang Bio is mainly focused on the research and development and industrialization of immune cell drugs
.
It is reported that the funds raised in this round will be mainly used for the construction of R&D facilities and the early development of general-purpose spot immune cell technology platforms and products
.
Gravel Bio, which focuses on the field of solid tumor immunotherapy, also completed a seed round of financing in July.
The investors are Hillhouse Ventures (lead investment), Xingze Capital, Junshi Bio, Decheng Capital, and Matrix China
.
It is understood that Sandstone Bio focuses on the development and application of tumor infiltrating lymphocytes (TIL), which the industry believes is a very competitive and industrialized technical direction in the field of solid tumor immunotherapy
.
In addition, Yuesai Biotechnology completed an angel round of financing of tens of millions of yuan at the end of August
.
This round of financing was led by Taifu Capital and jointly invested by Kunlun Capital and Hillhouse Ventures
.
It is reported that Yuesai Biology is an enterprise focusing on the development of a new generation of cell therapy drugs based on human pluripotent stem cell technology.
It is committed to technology research and product development in the field of stem cell therapy.
The research and development pipeline covers neurodegenerative diseases, rare diseases and tumors, etc.
.
This round of financing will be used for the landing of the Yuesai Biologics production and R&D center, supporting the formation of the team, and launching the safety evaluation and IND application of the UniXell DA001, the first Parkinson's disease cell therapy pipeline of the Yuesai Biologics
.
Gene editing technology has also shined in recent years, and has begun to be used in basic theoretical research and production applications, from the study of plant and animal gene functions to human gene therapy
.
In the field of gene therapy, related therapies have continuously made breakthroughs in clinical aspects in recent years, which have brought continuous innovations to the development of biomedicine.
In the future, it is expected to bring longer-term and better therapeutic effects to patients in the clinic
.
The company in the third quarter of this year, the number of dedicated editors gene therapy have announced the completion of the early financing, including bass Angke, sharp positive genes, gene sprouts, refine biology
.
Among them, Bethonco and Refine Biotech both received large-scale financing of 100 million yuan.
The former received nearly 100 million yuan in angel round financing.
This round of financing funds will be mainly used for the upgrade, product development, and product development of Bethonco’s unique gene editing NK platform and gene therapy platform.
The construction of the patent pool and related team building; the latter completed hundreds of millions of yuan in A+ round of financing, this round of financing is mainly used to promote the advancement of the pre-developed products into the clinical stage and support the systematic layout of pipelines
.
Looking back at this quarter, the domestic new drug R&D field is still active in financing.
A total of more than 80 companies have completed different rounds and types of financing.
From the perspective of the main R&D areas, cell therapy, Gene editing is frequently favored by capital
.
Cell technology is known as the third revolution in human medical history.
Cell therapy has great potential in cancer treatment.
Among them, chimeric antigen receptor-loaded T cell (CAR-T) therapy is more effective for patients with advanced tumors.
The good curative effect has led to an upsurge in immune cell therapy
.
2021 is the first year of the commercialization of domestic CAR-T cells.
Two domestic CAR-T products have been approved for listing.
The industry expects that CAR-T cell therapy is expected to usher in a major outbreak this year
.
In this context, capital is also accelerating its deployment in the field of cellular immunotherapy
.
For example, on July 30 this year, the newly established Xingyiang Biotech announced the completion of a US$40 million angel round of financing led by Eli Lilly Asia Fund.
This round of investment was led by Eli Lilly Asia Fund, IDG Capital and Sherpa Investment Follow the vote
.
Xingyiang Bio is mainly focused on the research and development and industrialization of immune cell drugs
.
It is reported that the funds raised in this round will be mainly used for the construction of R&D facilities and the early development of general-purpose spot immune cell technology platforms and products
.
Gravel Bio, which focuses on the field of solid tumor immunotherapy, also completed a seed round of financing in July.
The investors are Hillhouse Ventures (lead investment), Xingze Capital, Junshi Bio, Decheng Capital, and Matrix China
.
It is understood that Sandstone Bio focuses on the development and application of tumor infiltrating lymphocytes (TIL), which the industry believes is a very competitive and industrialized technical direction in the field of solid tumor immunotherapy
.
In addition, Yuesai Biotechnology completed an angel round of financing of tens of millions of yuan at the end of August
.
This round of financing was led by Taifu Capital and jointly invested by Kunlun Capital and Hillhouse Ventures
.
It is reported that Yuesai Biology is an enterprise focusing on the development of a new generation of cell therapy drugs based on human pluripotent stem cell technology.
It is committed to technology research and product development in the field of stem cell therapy.
The research and development pipeline covers neurodegenerative diseases, rare diseases and tumors, etc.
.
This round of financing will be used for the landing of the Yuesai Biologics production and R&D center, supporting the formation of the team, and launching the safety evaluation and IND application of the UniXell DA001, the first Parkinson's disease cell therapy pipeline of the Yuesai Biologics
.
Gene editing technology has also shined in recent years, and has begun to be used in basic theoretical research and production applications, from the study of plant and animal gene functions to human gene therapy
.
In the field of gene therapy, related therapies have continuously made breakthroughs in clinical aspects in recent years, which have brought continuous innovations to the development of biomedicine.
In the future, it is expected to bring longer-term and better therapeutic effects to patients in the clinic
.
The company in the third quarter of this year, the number of dedicated editors gene therapy have announced the completion of the early financing, including bass Angke, sharp positive genes, gene sprouts, refine biology
.
Among them, Bethonco and Refine Biotech both received large-scale financing of 100 million yuan.
The former received nearly 100 million yuan in angel round financing.
This round of financing funds will be mainly used for the upgrade, product development, and product development of Bethonco’s unique gene editing NK platform and gene therapy platform.
The construction of the patent pool and related team building; the latter completed hundreds of millions of yuan in A+ round of financing, this round of financing is mainly used to promote the advancement of the pre-developed products into the clinical stage and support the systematic layout of pipelines
.
